Neurologix (NRGX.OB), founded in 1999 by Dr. Matthew During and Dr. Michael Kaplitt, is not afraid to say it is a gene therapy company. When the company was founded, gene therapy was all the rage, but soon afterwards serious side-effects including at least one case of a deadly immune reaction appeared in human trials. The trials were put on hold and gene therapy was shunned by investors and companies alike. It now appears, not surprisingly perhaps, that those who persisted in its arduous development will reap the rewards....
